Ironwood Pharmaceuticals is projected to report Q3 2026 revenue of $119.99 million and earnings of $0.30 per share, with the stock currently trading at $3.50 relative to a $5.35 average analyst price target.
Investors are primarily tracking U.S. net sales of LINZESS, which analysts estimate at $262.5 million, to confirm that recent pediatric expansion and pricing adjustments are driving volume growth.
The report will also be scrutinized for updates on the clinical progress of apraglutide and the leadership transition following the announced retirement of CEO Tom McCourt. Additionally, management’s ability to reduce debt following the VectivBio acquisition while maintaining positive adjusted EBITDA guidance remains a top priority for market participants.